Analysts Anticipate Valeritas Holdings, Inc. (VLRX) Will Post Quarterly Sales of $5.60 Million

Wall Street analysts predict that Valeritas Holdings, Inc. (NASDAQ:VLRX) will report $5.60 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Valeritas’ earnings. Valeritas reported sales of $4.80 million in the same quarter last year, which indicates a positive year-over-year growth rate of 16.7%. The business is expected to report its next quarterly earnings report on Tuesday, February 20th.

According to Zacks, analysts expect that Valeritas will report full-year sales of $5.60 million for the current fiscal year, with estimates ranging from $19.88 million to $20.00 million. For the next year, analysts forecast that the company will report sales of $27.11 million per share, with estimates ranging from $26.53 million to $27.50 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Valeritas.

Valeritas (NASDAQ:VLRX) last issued its earnings results on Wednesday, November 8th. The company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.84) by $0.22. Valeritas had a negative return on equity of 820.08% and a negative net margin of 229.55%.

Separately, ValuEngine upgraded Valeritas from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.

Valeritas (NASDAQ VLRX) opened at $3.36 on Thursday. The company has a current ratio of 3.88, a quick ratio of 3.20 and a debt-to-equity ratio of 3.54. Valeritas has a 12-month low of $2.00 and a 12-month high of $40.00.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Valeritas Holdings, Inc. (VLRX) Will Post Quarterly Sales of $5.60 Million” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at

About Valeritas

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with's FREE daily email newsletter.

Leave a Reply